Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine? / ¿Podría ceftarolina ser una alternativa terapéutica frente a las infecciones por Staphylococcus epidermidis en el paciente crítico?

Introduction. Staphylococcus coagulasa negativo sigue generando interés en los pacientes críticos, debido a sus infecciones en los ingresos prolongados, en pacientes instrumentados y, debido a su resistencia a múltiples fármacos descrito, que incluyen la heterorresistencia a glicopéptidos y el aumento de la resistencia oxazolidinonas. Ceftarolina es una nueva cefalosporina con actividad frente a grampositivos resistentes, que, por ser un betalactámico, podría proporcionar un perfil de seguridad adecuado en el paciente crítico. El objetivo de este estudio fue determinar la actividad de ceftarolina y otros agentes antimicrobianos frente a cepas de Staphylococcus epidermidis resistente a meticilina y linezolid. Material y métodos. Estudiamos la sensibilidad de ceftarolina, tigeciclina, daptomicina y vancomicina en un total de sesenta y ocho aislamientos con significación clínica de S. epidermidis resistente a meticilina y linezolid en una Unidad de Cuidados Intensivos, usando E-test. Resultados. Todas las cepas fueron sensibles a los cuatro agentes antimicrobianos, con independencia del nivel de resistencia a linezolid. Conclusión. Ceftarolina podría ser una alternativa en el tratamiento de infecciones por S. epidermidis resistente a meticilina y linezolid en el paciente crítico (AU)

Introduction. Coagulase negative Staphylococcus continues generating interest in critically ill patients, due to their infections in extended admissions, in instrumented patients and due to their described multidrug resistance, which include glycopeptide heterorresistance and the increase in oxazolidinone resistance. Ceftaroline is a new cephalosporin with activity against resistant gram-positives, which, being betalactam, may provide adequate safety profile in the critical ill patient. The aim of this study was to determine the activity of ceftaroline and other antimicrobial agents against methicillin and linezolid-resistant Staphylococcus epidermidis. Material and methods. We studied susceptibility of ceftaroline, tigecycline, daptomycin and vancomycin in a total of sixty-eight methicillin and linezolid-resistant S. epidermidis isolates with clinical significance from an Intensive Care Unit, using E-test. Results. All strains were susceptible to the four antimicrobial agents, regardless of the level of resistance to linezolid. Conclusion. Ceftaroline could be an alternative in the treatment of methicillin and linezolid-resistant S. epidermidis infections in critically ill patients (AU)

Could ceftaroline be an alternative therapy for linezolid resistant Staphylococcus epidermidis infections in Intensive Care Medicine?

INTRODUCTION: Coagulase negative Staphylococcus continues generating interest in critically ill patients, due to their infections in extended admissions, in instrumented patients and due to their described multidrug resistance, which include glycopeptide heterorresistance and the increase in oxazolidinone resistance. Ceftaroline is a new cephalosporin with activity against resistant gram-positives, which, being betalactam, may provide adequate safety profile in the critical ill patient. The aim of this study was to determine the activity of ceftaroline and other antimicrobial agents against methicillin and linezolid-resistant Staphylococcus epidermidis. MATERIAL AND METHODS: We studied susceptibility of ceftaroline, tigecycline, daptomycin and vancomycin in a total of sixty-eight methicillin and linezolid-resistant S. epidermidis isolates with clinical significance from an Intensive Care Unit, using E-test. RESULTS: All strains were susceptible to the four antimicrobial agents, regardless of the level of resistance to linezolid. CONCLUSION: Ceftaroline could be an alternative in the treatment of methicillin and linezolid-resistant S. epidermidis infections in critically ill patients.